Diligence memo · auto-generated · as of July 2, 2026
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. has raised $543M over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Akcea Therapeutics, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Akcea Therapeutics, Inc. has raised $543M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $543M on 2015-12-18.
Most recent recorded round closed around 2015-12-18.
Valuation (modeled)modeled
Provath models Akcea Therapeutics, Inc. at approximately $19.7B (range $3.6B–$35.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 10.5 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Salix Pharmaceuticals Ltd, Moderna LLC, Compound Holdings I, LLC.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.